Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice.

AIMS/HYPOTHESIS The metabolic syndrome comprises a clustering of cardiovascular risk factors but the underlying mechanism is not known. Mice with targeted disruption of endothelial nitric oxide synthase (eNOS) are hypertensive and insulin resistant. We wondered, whether eNOS deficiency in mice is associated with a phenotype mimicking the human metabolic syndrome. METHODS AND RESULTS In addition to arterial pressure and insulin sensitivity (euglycaemic hyperinsulinaemic clamp), we measured the plasma concentration of leptin, insulin, cholesterol, triglycerides, free fatty acids, fibrinogen and uric acid in 10 to 12 week old eNOS-/- and wild type mice. We also assessed glucose tolerance under basal conditions and following a metabolic stress with a high fat diet. As expected eNOS-/- mice were hypertensive and insulin resistant, as evidenced by fasting hyperinsulinaemia and a roughly 30 percent lower steady state glucose infusion rate during the clamp. eNOS-/- mice had a 1.5 to 2-fold elevation of the cholesterol, triglyceride and free fatty acid plasma concentration. Even though body weight was comparable, the leptin plasma level was 30% higher in eNOS-/- than in wild type mice. Finally, uric acid and fibrinogen were elevated in the eNOS-/- mice. Whereas under basal conditions, glucose tolerance was comparable in knock out and control mice, on a high fat diet, knock out mice became significantly more glucose intolerant than control mice. CONCLUSIONS A single gene defect, eNOS deficiency, causes a clustering of cardiovascular risk factors in young mice. We speculate that defective nitric oxide synthesis could trigger many of the abnormalities making up the metabolic syndrome in humans.

[1]  U. Scherrer,et al.  Insulin resistance, a new target for nitric oxide‐delivery drugs , 2002, Fundamental & clinical pharmacology.

[2]  M. Matsuhisa,et al.  Association of -786T-C mutation of endothelial nitric oxide synthase gene with insulin resistance , 2002, Diabetologia.

[3]  P. Vollenweider,et al.  Insulin Resistance, Hyperlipidemia, and Hypertension in Mice Lacking Endothelial Nitric Oxide Synthase , 2001, Circulation.

[4]  C. Sartori,et al.  Insulin, nitric oxide and the sympathetic nervous system: at the crossroads of metabolic and cardiovascular regulation. , 1999, Journal of hypertension.

[5]  H. Itoh,et al.  Endothelial nitric oxide synthase gene is positively associated with essential hypertension. , 1998, Hypertension.

[6]  I. Godsland,et al.  Hyperleptinemia as a Component of a Metabolic Syndrome of Cardiovascular Risk , 1998 .

[7]  M. Taskinen,et al.  Insulin increases plasma leptin concentrations in normal subjects and patients with NIDDM , 1996, Diabetologia.

[8]  P. Vollenweider,et al.  Nitric oxide release accounts for insulin's vascular effects in humans. , 1994, The Journal of clinical investigation.

[9]  A. Quyyumi,et al.  Role of Endothelium‐Derived Nitric Oxide in the Abnormal Endothelium‐Dependent Vascular Relaxation of Patients With Essential Hypertension , 1993, Circulation.

[10]  G. Reaven Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[11]  H. Halkin,et al.  Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. , 1985, The Journal of clinical investigation.

[12]  R A Shaffer,et al.  State-of-the-art-lecture: Obesity-induced hypertension: new concepts from the emerging biology of obesity. , 1999, Hypertension.